Johns Hopkins University is expected to receive almost $6.4 million from the federal health department for a support program for people with dementia. The award, worth up to $6.38 million, is part of the federal Centers for Medicare and Medicaid Services’ Health Care Innovation Awards.
The award is contingent on final administrative approval by the federal health department.
Healthcare startups, and all startups for that matter, need investors and funding to stay alive. For this reason, MedCity is pleased to announce that investor Andrew Jay, MD, will be speaking at CONVERGE. Dr. Jay is the head of the medical solutions fund at HealthCare Fund at Siemens Venture Capital, which invests in companies focusing on imaging, diagnostics and health IT.
Jay will be speaking on the second day of MedCity CONVERGE at 9:20 a.m. The third annual CONVERGE is July 15-16 in Philadelphia.
Two private equity firms announced the formation of a $26.6 million fund that will focus exclusively on the aging marketplace and companies within it.
Chicago-based Ziegler and Ohio-based Link-age Ventures announced the close of the Longevity Fund, which aims to address a number of key issues affecting seniors. Among them: coordination of care, chronic disease management, reducing hospitalizations and re-admissions, disease prevention and wellness, aging and government funded programs and public health issues, according to the companies.
Maryland has one of the Top 10 best-buy colleges and universities, according to the 2015 edition of Fisk’s Guide to Colleges.
The University of Maryland, Baltimore County ranked No. 9 out of 44 schools in the U.S., United Kingdom and Canada.
The Frederick Innovative Technology Center Inc. is looking for business leaders to volunteer for its board of directors.
Preference will be given to those in private industry in the fields of life sciences, advance technology, finance, marketing and entrepreneur. The board meets the fourth Monday of each month.
Happy 10th anniversary to the National Institutes of Health’s Common Fund! It’s hard to believe that it’s been a decade since I joined then-NIH Director Elias Zerhouni at the National Press Club to launch this trans-NIH effort to catalyze innovation and speed progress across many fields of biomedical research.
Allow me to take this opportunity to share just a bit of the history and a few of the many achievements of this bold new approach to the support of science.
Healthcare Interactive Inc. — which sells Web-based software for companies to monitor medical costs in real time — has raised $8 million in funding.
The Series A funding in the Glenwood, Maryland-based company came from Grotech Ventures, which has more than $1.3 billion under management, and Harbert Venture Partners, an emerging growth-stage investor with $200 million under management.
It’s still a good time to go public.
Twenty-eight venture-backed companies completed initial public offerings during the second quarter, raising $4.9 billion. That was a 45 percent increase in dollars raised compared to the previous quarter, according to an analysis by Thomson Reuters and the National Venture Capital Association. It was the fifth consecutive quarter of more than 20 IPOs at venture-backed companies.
A cadre of venture capital firms could cash in from the wave of Bay Area biotech initial public offerings in the first half of the year.
Stalwart VCs such as Kleiner Perkins Caufield & Byers of Menlo Park and Domain Associates are among the venture capital firms whose names pop up most often in the IPOs of local life sciences companies through June. Among the other VCs are DAG Ventures of Palo Alto and Essex Woodlands Health Ventures in Palo Alto.
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement (“Agreement”) with HealthCare Royalty Partners (“HC Royalty”). Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram(TM) (treprostinil) Extended-Release Tablets by Supernus’ partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.
“We are pleased to have completed this royalty transaction, which strengthens our balance sheet and enhances our financial flexibility,” said Jack Khattar, President and Chief Executive Officer of Supernus. “The transaction allows us to partially monetize our royalty stream from Orenitram(TM) for a significant cash consideration while positioning Supernus to further benefit from the future upside potential of the product.”
